RT Journal Article
SR Electronic
T1 Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of an Ongoing Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20116988
DO 10.1101/2020.06.03.20116988
A1 Clayton B. Hess
A1 Zachary S. Buchwald
A1 William Stokes
A1 Jeffrey M. Switchenko
A1 Tahseen H. Nasti
A1 Brent D. Weinberg
A1 James P. Steinberg
A1 Karen D. Godette
A1 David Murphy
A1 Rafi Ahmed
A1 Walter J. Curran, Jr
A1 Mohammad K. Khan
YR 2020
UL http://medrxiv.org/content/early/2020/06/08/2020.06.03.20116988.abstract
AB Background Individuals with advanced age and comorbidities face higher risk of death from COVID-19, especially once ventilator-dependent. Respiratory decline in COVID-19 is mediated by a pneumonic aberrant immune cytokine storm. Low-dose radiation was used to treat pneumonia in the pre-antibiotic era. Radiation immunomodulatory effects may improve outcomes in COVID-19.Methods We performed a single-institution phase I/II trial evaluating the safety and efficacy of single-fraction, low-dose, whole-lung radiation for COVID-19 pneumonia. Eligible patients were hospitalized, had radiographic pneumonic infiltrates, required supplemental oxygen, and were clinically deteriorating.Results Of nine patients screened, five were treated with whole-lung radiation from April 2328, 2020 and followed for 7 days. Median age was 90 (range 64-94); four were nursing home residents with multiple comorbidities. Within 24 hours of radiation, three patients (60%) weaned from supplemental oxygen to ambient air, four (80%) exhibited radiographic improvement, and median Glasgow coma score improved from 10 to 14. A fourth patient (80% overall recovery) weaned from oxygen at hour 96. Mean time to clinical recovery was 35 hours. There were no acute skin, pulmonary, GI, GU toxicities.Conclusions In a small pilot trial of five oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity or worsening the cytokine storm. Low-dose whole-lung radiation appears to be safe, shows early promise of efficacy, and warrants larger prospective trials.Lay Summary Researchers at Emory University have completed treatment of cohort 1 of a pilot trial of low-dose lung irradiation for COVID-19 pneumonia. Five residents of nursing or group homes with COVID-19 outbreaks were hospitalized after testing positive for COVID-19. Each had pneumonia visible on chest x-ray, required supplemental oxygen, and had clinically declined. A single treatment of low-dose (1.5 Gy) radiation to both lungs was delivered over 10-15 minutes. Within 24 hours, four patients rapidly improved their breathing, recovering at an average of 1.5 days (range 3 to 96 hours), and had either been discharged (three) or were preparing for discharge (one) by day 14. Blood tests and repeat imaging confirmed that low-dose radiation appeared safe and effective in reducing their COVID-19 symptoms. Further trials are warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04366791Funding StatementThis trial was funded by the institution funds, and voluntary efforts by the investigators. No external funding was used to support this trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory IRB approved the protocol and listed it on Clinical Trial website.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript that has been uploaded to the server.